Many of the current production workflows are reliant on basal media in batch-mode, which can require a long and costly optimization of the HEK293 cell culture conditions to increase their efficiency.

A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for drug-resistant breast and prostate cancer, based around a new target known as FOXA1.